Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model

  • Authors:
    • Xiao‑Hua Zhang
    • En‑Qi Qiao
    • Zhenzhen Gao
    • Hua‑Qing Yuan
    • Pei‑Fen Cai
    • Xiao‑Min Li
    • Yan‑Hong Gu
  • View Affiliations

  • Published online on: May 14, 2013     https://doi.org/10.3892/ol.2013.1345
  • Pages: 69-74
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In this study, we evaluated the efficacy and intestinal side effects of the selective inhibitor of vascular endothelial growth factor (VEGF) receptors, axitinib and/or dacarbazine (DTIC), in a B16F1 melanoma xenograft model. C57BL/6 mice were subcutaneously inoculated with B16F1 melanoma cells. The study was randomized into four groups receiving either 0.5% carboxyl methylcellulose, DTIC, axitinib or a combination of DTIC and axitinib. When the experimental period was complete, the tumor tissues from each mouse were excised, photographed and weighed. The tumor and intestinal tissues were harvested with 4% paraformaldehyde, and paraffin‑embedded sections were prepared for hematoxylin and eosin staining, immunohistochemical staining (with antibody specific to proliferating cell nuclear antibody) and terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling assays. The expression of the VEGF and matrix metalloproteinase 9 genes was analyzed using real‑time polymerase chain reaction. No significant benefit to treatment with a combination of axitinib and DTIC, as opposed to axitinib alone, was observed; however, the combined treatment did not enhance the level of enteritis compared with that observed in the axitinb group. In addition, axitinib, as a single agent, demonstrated an improved treatment efficacy compared with DTIC. Therefore, axitinib represents a potential novel, efficient and safe anticancer agent, suggesting a possible use for this schedule in treating melanomas that are less sensitive to DTIC.
View Figures
View References

Related Articles

Journal Cover

July 2013
Volume 6 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang XH, Qiao EQ, Gao Z, Yuan HQ, Cai PF, Li XM and Gu YH: Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model. Oncol Lett 6: 69-74, 2013
APA
Zhang, X., Qiao, E., Gao, Z., Yuan, H., Cai, P., Li, X., & Gu, Y. (2013). Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model. Oncology Letters, 6, 69-74. https://doi.org/10.3892/ol.2013.1345
MLA
Zhang, X., Qiao, E., Gao, Z., Yuan, H., Cai, P., Li, X., Gu, Y."Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model". Oncology Letters 6.1 (2013): 69-74.
Chicago
Zhang, X., Qiao, E., Gao, Z., Yuan, H., Cai, P., Li, X., Gu, Y."Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model". Oncology Letters 6, no. 1 (2013): 69-74. https://doi.org/10.3892/ol.2013.1345